Trump administration plans prescription drug direct sales platform: bypass pharmacies, promote lower drug prices

```

The Trump administration is discussing the creation of a direct prescription drug sales platform to help patients purchase discounted prescription drugs directly from pharmaceutical companies.

According to media reports on September 19, U.S. government officials are discussing creating a website that may be named after President Trump, making it easier for patients to purchase discounted prescription drugs directly from pharmaceutical companies. The report, citing informed sources, revealed that "TrumpRx" is one of the brand names under consideration.

The website will serve as a connecting bridge between patients and pharmaceutical sales platforms, allowing users to search for specific drugs and obtain related purchasing channels. The aim is to realize direct sales of drugs, bypassing traditional pharmacy channels.

A spokesperson for the U.S. Centers for Medicare & Medicaid Services stated that the agency is committed to implementing President Trump's directive to lower prescription drug prices and ensure that Americans can obtain medications at fairer and more transparent prices. However, the plan has not yet been finalized and discussions are still ongoing.

Pharmaceutical giants actively respond to the direct sales model

According to reports, President Trump sent letters to 17 major global pharmaceutical companies this July.

The letter required pharmaceutical companies to immediately lower the prices of existing drugs under the U.S. federal Medicaid program, and to ensure that future newly launched drug prices would be consistent with overseas markets, otherwise they would face penalties.

Another key requirement in Trump’s letter is that companies should create platforms to directly sell some high-demand drugs enjoying large insurance discounts to patients or businesses, and the proposed “TrumpRx” website is a concrete measure to achieve this requirement.

It is worth noting that this “direct-to-consumer” (DTC) model has already received positive responses from some major pharmaceutical companies.

Eli Lilly was the first to launch an innovative model, allowing patients to obtain cheaper weight loss drugs after consulting with doctors via telemedicine platforms. Pfizer and Bristol Myers Squibb, after discussions with the White House earlier this year, launched new direct-to-consumer platforms for their blood thinner, Eliquis.

The direct sales program enables patients to bypass pharmacy benefit managers. U.S. pharmaceutical companies believe these intermediaries reduce their income and affect patient access to medication.

Multi-pronged drug price control strategies

Among a series of policies aimed at reshaping the pharmaceutical market, the U.S. government has also adopted other regulatory measures.

For example, the government announced it would more strictly enforce regulations on drug advertisements on television and social media, attempting to curb marketing activities that may increase demand.

In addition, to force companies to move more manufacturing lines back to the U.S., Trump also threatened to impose tariffs as high as 250% on imported drugs.

From direct price negotiations, restructuring sales channels, to advertising regulations and tariff threats, the U.S. government is forcing the pharmaceutical industry to restructure its operations and business models in the U.S. market.

Risk warning and disclaimerThe market carries risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the special investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular situation. Investment is at your own risk. ```